Loading...
XSHE
002332
Market cap1.41bUSD
Sep 17, Last price  
10.16CNY
1D
-1.07%
1Q
11.89%
Jan 2017
18.41%
IPO
24.05%
Name

Zhejiang Xianju Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
25.30
P/S
2.51
EPS
0.40
Div Yield, %
2.95%
Shrs. gr., 5y
1.62%
Rev. gr., 5y
1.53%
Revenues
4.00b
-2.98%
765,330,681966,789,3371,133,516,5221,276,721,0341,500,980,9331,689,209,5981,992,191,5442,315,040,5652,470,533,0192,480,246,1532,503,730,3452,852,555,2623,621,754,7133,708,545,5304,018,872,7724,337,150,9644,379,825,6954,123,418,5844,000,693,148
Net income
397m
-29.46%
49,529,72464,636,46165,037,69988,841,792120,165,635132,869,614120,557,25460,591,46856,695,716106,551,038146,186,888206,630,126301,362,969410,368,585504,509,427619,325,646749,411,381563,083,493397,178,995
CFO
399m
-33.05%
53,052,17996,534,59036,030,822104,678,023155,292,369147,627,79833,427,87163,461,725141,638,736199,607,086155,905,554167,466,085193,266,995519,805,113789,233,376676,151,765609,284,602595,482,358398,655,375
Dividend
Jun 05, 20240.3 CNY/sh

Profile

Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers active pharmaceutical ingredients, such as steroid drugs, and male and female hormones; intermediates; and finished formulations in the form of tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-injections. Zhejiang Xianju Pharmaceutical Co.,Ltd. was founded in 1972 and is based in Xianju, China.
URL
http://www.xjpharma.com/
IPO date
Jan 12, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,000,693
-2.98%
4,123,419
-5.85%
4,379,826
0.98%
Cost of revenue
2,936,190
3,163,426
3,457,615
Unusual Expense (Income)
NOPBT
1,064,503
959,993
922,210
NOPBT Margin
26.61%
23.28%
21.06%
Operating Taxes
98,404
79,562
124,506
Tax Rate
9.24%
8.29%
13.50%
NOPAT
966,099
880,431
797,704
Net income
397,179
-29.46%
563,083
-24.86%
749,411
21.00%
Dividends
(298,191)
(299,766)
(148,381)
Dividend yield
3.02%
2.38%
1.33%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
8,510
167,395
146,162
Long-term debt
41,159
58,249
202,658
Deferred revenue
97,254
57,857
54,526
Other long-term liabilities
205,294
9,528
8,485
Net debt
(1,635,784)
(1,730,858)
(1,672,648)
Cash flow
Cash from operating activities
398,655
595,482
609,285
CAPEX
(207,587)
(234,632)
Cash from investing activities
(180,422)
(199,630)
358,066
Cash from financing activities
(465,825)
(463,847)
FCF
372,034
671,403
696,358
Balance
Cash
1,381,891
1,660,044
1,720,466
Long term investments
303,562
296,458
301,002
Excess cash
1,485,418
1,750,331
1,802,477
Stockholders' equity
3,661,578
3,580,903
3,780,907
Invested Capital
4,744,591
4,362,990
4,056,021
ROIC
21.22%
20.92%
19.59%
ROCE
17.09%
15.70%
15.74%
EV
Common stock shares outstanding
992,947
987,866
989,205
Price
9.94
-22.16%
12.77
13.01%
11.30
-14.39%
Market cap
9,869,898
-21.76%
12,615,046
12.86%
11,178,015
-14.39%
EV
8,278,783
10,928,113
9,555,360
EBITDA
1,291,248
1,180,081
1,115,210
EV/EBITDA
6.41
9.26
8.57
Interest
5,768
6,641
6,288
Interest/NOPBT
0.54%
0.69%
0.68%